PennyStockChaser.com: Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC …
Trading Markets (press release), CA

Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. …

Cyclacel & Dartmouth Researchers Report Novel Mechanism of Action …
Stockhouse, Canada

Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. …

Varian RapidArc Technology Used with Novalis Tx System for First …
PR Newswire (press release), NY

Doctors at Inselspital, the Bern University Hospital, used the Novalis Tx platform from Varian and BrainLAB to treat a patient suffering simultaneous skin cancer of the nose and an aggressive nasopharyngeal cancer with image-guided IMRT (intensity …

Cyclacel Pharmaceuticals Announces Multiple Presentations At …
MarketWatch (press release)

Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. …

Stories of faith
Philippine Star, Philippines

Yes, I did ask God that question when I was diagnosed to be suffering from nasopharyngeal cancer, Stage 3, early last year. After all, being a basketball player, I take good care of my health. I don't smoke; I don't drink; I don't even have a nightlife …

Cyclacel Pharmaceuticals Announces Suspension of Quarterly …
MarketWatch (press release)

Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in patients with solid tumors. …

GSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: an …
7thSpace Interactive (press release), NY

Previous evidence implicates polymorphisms of GSTM1 and GSTT1, candidates of phase enzymes, as risk factors for various cancers. A number of studies have conducted on the association of GSTM1 and GSTT1 polymorphism with susceptibility to nasopharyngeal …

University Hospitals in Germany, Switzerland use Varian's RapidArc …
Trading Markets (press release), CA

Hilke Vorwerk, physician at Gottingen University Hospital, said: "Today we are treating a nasopharyngeal cancer patient with a boost of RapidArc because we could not create an acceptable IMRT plan, so there are clearly some patients for whom RapidArc …

Cyclacel Pharmaceuticals Announces Financial Results for Fourth …
FOXBusiness

Continued enrollment in a seliciclib Phase 2 randomized trial in patients with nasopharyngeal cancer (NPC); * Completed enrollment in the seliciclib APPRAISE Phase 2 randomized trial in lung cancer; * Published combination data showing synergy between …

University Hospitals in Germany and Switzerland Treat Complex …
FOXBusiness

"Today we are treating a nasopharyngeal cancer patient with a boost of RapidArc because we could not create an acceptable IMRT plan, so there are clearly some patients for whom RapidArc offers a more appropriate treatment," says physician Dr. Hilke …